| Therapeutic | Ofatumumab |
| Target | MS4A1 |
| Heavy Chain | EVQLVESGGGLVQPGRSLRLSCAASGFTFNDYAMHWVRQAPGKGLEWVSTISWNSGSIGYADSVKGRFTISRDNAKKSLYLQMNSLRAEDTALYYCAKDIQYGNYYYGMDVWGQGTTVTVSS |
| Light Chain | EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTRLEIK |
| 100% seqID Fv Structure | 3giz%3AHL%2F6y92%3AHL%3ACD [Fvs: ] |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
| 100% seqID Structure | 3giz%3AHL%2F6y92%3AHL%3ACD [Fvs: ] |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G1 |
| Highest Clinical Trial (August '23) | Approved |
| Estimated Status (August '23) | Active |
| Recorded Developmental Technology | Medarex HuMAb Mouse |
| INN Year Proposed | 2005 |
| INN Year Recommended | 2006 |
| Companies Involved | Genmab%3BGlaxoSmithKline%3BMundipharma International%3BNational Cancer Centre %28Singapore%29%3BNovartis%3BRoswell Park Cancer Institute%3BUniversity Health Network |
| Conditions Approved | Chronic lymphocytic leukaemia |
| Conditions Active | B-cell lymphoma%3BDiffuse large B cell lymphoma%3BFollicular lymphoma%3BMultiple sclerosis%3BMarginal zone B-cell lymphoma%3BPrecursor cell lymphoblastic leukaemia-lymphoma |
| Conditions Discontinued | Neuromyelitis optica%3BPemphigus vulgaris%3BRheumatoid arthritis%3BWaldenstrom%27s macroglobulinaemia |
| Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
